Serotonin Control of Impulsivity in Tourette Disorder (ARITEP)
Tourette Disorder
About this trial
This is an interventional treatment trial for Tourette Disorder focused on measuring Tourette, Serotonin, Impulsivity, Neuroimaging
Eligibility Criteria
Inclusion Criteria * : Male or Female Diagnosed with a Tourette Disorder following the DSM-5 Age between 18-65 years Member of a social security scheme in France Freely-given informed consent to participate to this study (written form) With a current treatment by aripiprazole already scheduled With Tics compatible with TEP/fMRI exams Having (for women only) effective contraception throughout participation in the study. Exclusion Criteria * : Male or Female A serious not controlled psychiatric comorbidity A serious, evolving or debilitating pathology with a potential influence on the study Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin) Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia) Women breastfeeding Protected or restricted person (administratively or in judicial terms) Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study Do not speak french
Sites / Locations
- Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon
- Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière
Arms of the Study
Arm 1
Experimental
Tourette disorder
20 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.